Showing 5581-5590 of 5771 results for "".
- Visulytix’s AI Tool Equivalent to Human Experts in Glaucoma Detectionhttps://modernod.com/news/visulytixs-ai-tool-equivalent-to-human-experts-in-glaucoma-detection/2480181/Visulytix announced that Pegasus-disc, its artificial intelligence (AI) decision support tool for the analysis of retinal images, has been shown to perform similarly to the consensus opinion of human experts when detecting glaucoma from optic disc images. This follows a study conducted on the ima
- OCTANe Partners with the CEDARS/ASPENS to Enhance Offeringshttps://modernod.com/news/octane-partners-with-the-cedars-aspens-to-enhance-offerings/2480182/OCTANe announced that it has partnered with the CEDARS/ASPENS Society to enhance offerings around ophthalmic surgery for its annual Ophthalmology Technology Summit (OTS). OTS 2018 will be held June 29 at the Fashion
- Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018https://modernod.com/news/ocugen-presents-preclinical-efficacy-data-of-its-proprietary-nanoemulsion-technology-at-arvo-2018/2480184/Ocugen announced that it presented additional preclinical findings in a poster highlighting the potential efficacy of its unique, patented nanoemulsion formulation of brimonidine tartrate (OCU300) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndromehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome/2480185/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology)
- Glaucoma Research Foundation Speeds Search for a Curehttps://modernod.com/news/glaucoma-research-foundation-speeds-search-for-a-cure/2480187/Glaucoma Research Foundation has announced the celebration of its 40th anniversary year, the board approval of its new strategic plan, and an expanded capital campaign designed to accelerate research towards a cure. Commemorated at an April 24 annual dinner at the War Memorial in San F
- New Novartis Phase 3 Data for Brolucizumab Demonstrate Reliability of 12-Week Treatment Intervalhttps://modernod.com/news/new-novartis-phase-3-data-for-brolucizumab-demonstrate-reliability-of-12-week-treatment-interval/2480190/Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (AMD) from a prespecified secondary analysis of the phase 3 HAWK and HARRIER trials. The findings showed that patients assessed as appropriate for a 12-week treatment frequency during
- Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-presents-dry-eye-disease-phase-2a-clinical-trial-results-at-arvo/2480191/Aldeyra Therapeutics presented the results of a randomized, double-masked, parallel-group phase 2a dry eye disease clinical trial of topical ocular reproxalap at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. The primary objective of the trial, to select a fo
- Johnson & Johnson Vision Presents New Data on Silicone Hydrogel Contact Lens Muco-Adhesive Propertieshttps://modernod.com/news/johnson-johnson-vision-presents-new-data-on-silicone-hydrogel-contact-lens-muco-adhesive-properties/2480192/Johnson & Johnson Vision presented new data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Honolulu, Hawaii. The data measured how the extent of crosslinking affects muco-adhesion in a laboratory study with corneal epithel
- Bausch + Lomb Will Present Scientific and Clinical Research During ARVO Meeinghttps://modernod.com/news/bausch-lomb-will-present-scientific-and-clinical-research-during-arvo-meeing/2480199/Bausch + Lomb announced that nearly a dozen scientific posters will address the results of studies featuring several of the company’s current product offerings and pipeline programs in its Consumer Health Care, Pharmaceuticals and Surgical businesses during the Association for Research in Vision
- ThromboGenics Initiates Phase 2 Clinical Study Evaluating Anti-PlGF in Combination With Anti-VEGF for Treatment of DMEhttps://modernod.com/news/thrombogenics-initiates-phase-2-clinical-study-evaluating-anti-plgf-in-combination-with-anti-vegf-for-treatment-of-dme/2480200/ThromboGenics announced that it has successfully enrolled the first patient in a phase 2 active-controlled, masked, multicenter study to evaluate the efficacy and safety of THR-317 administered in combination with ranibizumab (Lucentis, Novartis), for the treatment of DME (NCT03499223). TH